Nyxoah price target raised to $27 from $20 at Stifel

Stifel raised the firm’s price target on Nyxoah to $27 from $20 and keeps a Buy rating on the shares after Nyxoah announced their U.S. DREAM pivotal trial hit the primary endpoints of AHI and ODI, which will allow Nyxoah to file its fourth and final PMA module. The company expects FDA approval in late-2024 or early-2025, notes the analyst, who views DREAM’s “superior results” helping Nyxoah from a commercialization perspective.